Christine Poulos1, Elizabeth Kinter2, Jui-Chen Yang3, John F P Bridges4, Joshua Posner3, Erika Gleißner5, Axel Mühlbacher6, Bernd Kieseier7. 1. RTI Health Solutions, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC 27709, USA. 2. Biogen, Cambridge, MA, USA. 3. RTI Health Solutions, Research Triangle Park, NC, USA. 4. Johns Hopkins University, Baltimore, MD, USA. 5. Biogen, Ismaning, Germany. 6. Hochschule Neubrandenburg, Germany. 7. University of Düsseldorf, Düsseldorf, Germany.
Abstract
OBJECTIVES: The aim of this study was to assess the relative importance of features of a hypothetical injectable disease-modifying treatment for patients with multiple sclerosis using a discrete-choice experiment. METHODS: German residents at least 18 years of age with a self-reported physician diagnosis of multiple sclerosis completed a 25-30 minute online discrete-choice experiment. Patients were asked to choose one of two hypothetical injectable treatments for multiple sclerosis, defined by different levels of six attributes (disability progression, the number of relapses in the next 4 years, injection time, frequency of injections, presence of flu-like symptoms, and presence of injection-site reactions). The data were analyzed using a random-parameters logit model. RESULTS: Of 202 adults who completed the survey, results from 189 were used in the analysis. Approximately 50% of all patients reported a diagnosis of relapsing-remitting multiple sclerosis, and 31% reported secondary progressive multiple sclerosis. Approximately 71% of patients had current or prior experience with injectable multiple sclerosis medication. Approximately 53% had experienced flu-like symptoms caused by their medication, and 47% had experienced mild injection-site reactions. At least one significant difference was seen between levels in all attributes, except injection time. The greatest change in relative importance between levels of an attribute was years until symptoms get worse from 1 to 4 years. The magnitude of this difference was about twice that of relapses in the next 4 years, frequency of injections, and flu-like symptoms. CONCLUSIONS: Most attributes examined in this experiment had an influence on patient preference. Patients placed a significant value on improvements in the frequency of dosing and disability progression. Results suggest that changes in injection frequency can be as important as changes in efficacy and safety attributes. Understanding which attributes of injectable therapies influence patient preference could potentially improve outcomes and adherence in patients with multiple sclerosis.
OBJECTIVES: The aim of this study was to assess the relative importance of features of a hypothetical injectable disease-modifying treatment for patients with multiple sclerosis using a discrete-choice experiment. METHODS: German residents at least 18 years of age with a self-reported physician diagnosis of multiple sclerosis completed a 25-30 minute online discrete-choice experiment. Patients were asked to choose one of two hypothetical injectable treatments for multiple sclerosis, defined by different levels of six attributes (disability progression, the number of relapses in the next 4 years, injection time, frequency of injections, presence of flu-like symptoms, and presence of injection-site reactions). The data were analyzed using a random-parameters logit model. RESULTS: Of 202 adults who completed the survey, results from 189 were used in the analysis. Approximately 50% of all patients reported a diagnosis of relapsing-remitting multiple sclerosis, and 31% reported secondary progressive multiple sclerosis. Approximately 71% of patients had current or prior experience with injectable multiple sclerosis medication. Approximately 53% had experienced flu-like symptoms caused by their medication, and 47% had experienced mild injection-site reactions. At least one significant difference was seen between levels in all attributes, except injection time. The greatest change in relative importance between levels of an attribute was years until symptoms get worse from 1 to 4 years. The magnitude of this difference was about twice that of relapses in the next 4 years, frequency of injections, and flu-like symptoms. CONCLUSIONS: Most attributes examined in this experiment had an influence on patient preference. Patients placed a significant value on improvements in the frequency of dosing and disability progression. Results suggest that changes in injection frequency can be as important as changes in efficacy and safety attributes. Understanding which attributes of injectable therapies influence patient preference could potentially improve outcomes and adherence in patients with multiple sclerosis.
Authors: John F P Bridges; A Brett Hauber; Deborah Marshall; Andrew Lloyd; Lisa A Prosser; Dean A Regier; F Reed Johnson; Josephine Mauskopf Journal: Value Health Date: 2011-04-22 Impact factor: 5.725
Authors: V Devonshire; Y Lapierre; R Macdonell; C Ramo-Tello; F Patti; P Fontoura; L Suchet; R Hyde; I Balla; E M Frohman; B C Kieseier Journal: Eur J Neurol Date: 2011-01 Impact factor: 6.089
Authors: Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman Journal: J Neurol Date: 2009-04-27 Impact factor: 4.849
Authors: Stephanie C Steinberg; Richard J Faris; Cyril F Chang; Andrew Chan; Mark A Tankersley Journal: Clin Drug Investig Date: 2010 Impact factor: 2.859
Authors: Edward J D Webb; David Meads; Ieva Eskyte; Natalie King; Naila Dracup; Jeremy Chataway; Helen L Ford; Joachim Marti; Sue H Pavitt; Klaus Schmierer; Ana Manzano Journal: Patient Date: 2018-08 Impact factor: 3.883
Authors: Jeri Burtchell; Daisy Clemmons; Joann Clemmons; Tim Sabutis; Adeline Rosenberg; Jennifer Graves; Michael L Sweeney; John Kramer; Marina Ziehn; Brandon Brown; Jamie L Weiss; Ahmed Z Obeidat Journal: Neurol Ther Date: 2022-05-24
Authors: Ingrid E H Kremer; Silvia M A A Evers; Peter J Jongen; Trudy van der Weijden; Ilona van de Kolk; Mickaël Hiligsmann Journal: PLoS One Date: 2016-11-03 Impact factor: 3.240